Tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) receptor (VEGFR), such as sunitinib, sorafenib, pazopanib, regorafenib, axitinib, cabozantinib, lenvatinib, and tivozanib, have transformed the treatment of renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and thyroid cancer, among others. This evidence concerns the gene KDR and renal cell carcinoma.